These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 33722697)

  • 1. Novel high-intensive cholesterol-lowering therapies do not ameliorate knee OA development in humanized dyslipidemic mice.
    van Gemert Y; Kozijn AE; Pouwer MG; Kruisbergen NNL; van den Bosch MHJ; Blom AB; Pieterman EJ; Weinans H; Stoop R; Princen HMG; van Lent PLEM
    Osteoarthritis Cartilage; 2021 Sep; 29(9):1314-1323. PubMed ID: 33722697
    [TBL] [Abstract][Full Text] [Related]  

  • 2. IL-1β inhibition combined with cholesterol-lowering therapies decreases synovial lining thickness and spontaneous cartilage degeneration in a humanized dyslipidemia mouse model.
    van Gemert Y; Kruisbergen NNL; Blom AB; van den Bosch MHJ; van der Kraan PM; Pieterman EJ; Princen HMG; van Lent PLEM
    Osteoarthritis Cartilage; 2023 Mar; 31(3):340-350. PubMed ID: 36442605
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intensive cholesterol-lowering treatment reduces synovial inflammation during early collagenase-induced osteoarthritis, but not pathology at end-stage disease in female dyslipidemic E3L.CETP mice.
    van Gemert Y; Blom AB; Di Ceglie I; Walgreen B; Helsen M; Sloetjes A; Vogl T; Roth J; Kruisbergen NNL; Pieterman EJ; Princen HMG; van der Kraan PM; van Lent PLEM; van den Bosch MHJ
    Osteoarthritis Cartilage; 2023 Jul; 31(7):934-943. PubMed ID: 36898656
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Alirocumab, evinacumab, and atorvastatin triple therapy regresses plaque lesions and improves lesion composition in mice.
    Pouwer MG; Pieterman EJ; Worms N; Keijzer N; Jukema JW; Gromada J; Gusarova V; Princen HMG
    J Lipid Res; 2020 Mar; 61(3):365-375. PubMed ID: 31843957
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Beneficial effects of brown fat activation on top of PCSK9 inhibition with alirocumab on dyslipidemia and atherosclerosis development in APOE*3-Leiden.CETP mice.
    Zhou E; Li Z; Nakashima H; Choukoud A; Kooijman S; Berbée JFP; Rensen PCN; Wang Y
    Pharmacol Res; 2021 May; 167():105524. PubMed ID: 33667684
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Osteoarthritis development is induced by increased dietary cholesterol and can be inhibited by atorvastatin in APOE*3Leiden.CETP mice--a translational model for atherosclerosis.
    Gierman LM; Kühnast S; Koudijs A; Pieterman EJ; Kloppenburg M; van Osch GJ; Stojanovic-Susulic V; Huizinga TW; Princen HM; Zuurmond AM
    Ann Rheum Dis; 2014 May; 73(5):921-7. PubMed ID: 23625977
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High LDL levels lead to increased synovial inflammation and accelerated ectopic bone formation during experimental osteoarthritis.
    de Munter W; van den Bosch MH; Slöetjes AW; Croce KJ; Vogl T; Roth J; Koenders MI; van de Loo FA; van den Berg WB; van der Kraan PM; van Lent PL
    Osteoarthritis Cartilage; 2016 May; 24(5):844-55. PubMed ID: 26687826
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Variable cartilage degradation in mice with diet-induced metabolic dysfunction: food for thought.
    Kozijn AE; Gierman LM; van der Ham F; Mulder P; Morrison MC; Kühnast S; van der Heijden RA; Stavro PM; van Koppen A; Pieterman EJ; van den Hoek AM; Kleemann R; Princen HMG; Mastbergen SC; Lafeber FPJG; Zuurmond AM; Bobeldijk I; Weinans H; Stoop R
    Osteoarthritis Cartilage; 2018 Jan; 26(1):95-107. PubMed ID: 29074298
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Protective effects of mitochondria-targeted antioxidants and statins on cholesterol-induced osteoarthritis.
    Farnaghi S; Prasadam I; Cai G; Friis T; Du Z; Crawford R; Mao X; Xiao Y
    FASEB J; 2017 Jan; 31(1):356-367. PubMed ID: 27737897
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of alirocumab on individuals with type 2 diabetes, high triglycerides, and low high-density lipoprotein cholesterol.
    Colhoun HM; Leiter LA; Müller-Wieland D; Cariou B; Ray KK; Tinahones FJ; Domenger C; Letierce A; Israel M; Samuel R; Del Prato S
    Cardiovasc Diabetol; 2020 Feb; 19(1):14. PubMed ID: 32035487
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cholesterol accumulation caused by low density lipoprotein receptor deficiency or a cholesterol-rich diet results in ectopic bone formation during experimental osteoarthritis.
    de Munter W; Blom AB; Helsen MM; Walgreen B; van der Kraan PM; Joosten LA; van den Berg WB; van Lent PL
    Arthritis Res Ther; 2013 Nov; 15(6):R178. PubMed ID: 24286458
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alirocumab inhibits atherosclerosis, improves the plaque morphology, and enhances the effects of a statin.
    Kühnast S; van der Hoorn JW; Pieterman EJ; van den Hoek AM; Sasiela WJ; Gusarova V; Peyman A; Schäfer HL; Schwahn U; Jukema JW; Princen HM
    J Lipid Res; 2014 Oct; 55(10):2103-12. PubMed ID: 25139399
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Active involvement of alarmins S100A8 and S100A9 in the regulation of synovial activation and joint destruction during mouse and human osteoarthritis.
    van Lent PL; Blom AB; Schelbergen RF; Slöetjes A; Lafeber FP; Lems WF; Cats H; Vogl T; Roth J; van den Berg WB
    Arthritis Rheum; 2012 May; 64(5):1466-76. PubMed ID: 22143922
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy, safety and tolerability of atorvastatin in dyslipidemic subjects with advanced (non-nephrotic) and endstage chronic renal failure.
    Saltissi D; Westhuyzen J; Morgan C; Healy H
    Clin Exp Nephrol; 2006 Sep; 10(3):201-9. PubMed ID: 17009078
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intra-articular Injections of Platelet-Rich Plasma Releasate Reduce Pain and Synovial Inflammation in a Mouse Model of Osteoarthritis.
    Khatab S; van Buul GM; Kops N; Bastiaansen-Jenniskens YM; Bos PK; Verhaar JA; van Osch GJ
    Am J Sports Med; 2018 Mar; 46(4):977-986. PubMed ID: 29373806
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Alirocumab therapy in individuals with type 2 diabetes mellitus and atherosclerotic cardiovascular disease: analysis of the ODYSSEY DM-DYSLIPIDEMIA and DM-INSULIN studies.
    Ray KK; Del Prato S; Müller-Wieland D; Cariou B; Colhoun HM; Tinahones FJ; Domenger C; Letierce A; Mandel J; Samuel R; Bujas-Bobanovic M; Leiter LA
    Cardiovasc Diabetol; 2019 Nov; 18(1):149. PubMed ID: 31706300
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Procyanidin B3 prevents articular cartilage degeneration and heterotopic cartilage formation in a mouse surgical osteoarthritis model.
    Aini H; Ochi H; Iwata M; Okawa A; Koga D; Okazaki M; Sano A; Asou Y
    PLoS One; 2012; 7(5):e37728. PubMed ID: 22629448
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk Categorization Using New American College of Cardiology/American Heart Association Guidelines for Cholesterol Management and Its Relation to Alirocumab Treatment Following Acute Coronary Syndromes.
    Roe MT; Li QH; Bhatt DL; Bittner VA; Diaz R; Goodman SG; Harrington RA; Jukema JW; Lopez-Jaramillo P; Lopes RD; Louie MJ; Moriarty PM; Szarek M; Vogel R; White HD; Zeiher AM; Baccara-Dinet MT; Steg PG; Schwartz GG
    Circulation; 2019 Nov; 140(19):1578-1589. PubMed ID: 31475572
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Management of Hypercholesterolemia, Appropriateness of Therapeutic Approaches and New Drugs in Patients with High Cardiovascular Risk.
    Agabiti Rosei E; Salvetti M
    High Blood Press Cardiovasc Prev; 2016 Sep; 23(3):217-30. PubMed ID: 27567901
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-PCSK9 antibodies inhibit pro-atherogenic mechanisms in APOE*3Leiden.CETP mice.
    Schuster S; Rubil S; Endres M; Princen HMG; Boeckel JN; Winter K; Werner C; Laufs U
    Sci Rep; 2019 Jul; 9(1):11079. PubMed ID: 31366894
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.